IRDS
MCID: RSP007
MIFTS: 30

Respiratory Distress Syndrome, Infant (IRDS)

Categories: Rare diseases

Aliases & Classifications for Respiratory Distress Syndrome, Infant

MalaCards integrated aliases for Respiratory Distress Syndrome, Infant:

Name: Respiratory Distress Syndrome, Infant 52
Hyaline Membrane Disease 52 71
Rds - Infants 52 71
Infantile Respiratory Distress Syndrome 52
Neonatal Respiratory Distress Syndrome 52
Respiratory Distress Syndrome, Newborn 71
Irds 52
Nrds 52

Classifications:



External Ids:

UMLS 71 C0020192 C0035220 C2931829

Summaries for Respiratory Distress Syndrome, Infant

MalaCards based summary : Respiratory Distress Syndrome, Infant, also known as hyaline membrane disease, is related to newborn respiratory distress syndrome and choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction, and has symptoms including dyspnea, hemoptysis and apnea. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and testes.

Related Diseases for Respiratory Distress Syndrome, Infant

Diseases related to Respiratory Distress Syndrome, Infant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 newborn respiratory distress syndrome 12.2
2 choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction 12.1
3 peroxisome biogenesis disorder 1b 12.1
4 refsum disease, infantile form 11.9
5 respiratory distress syndrome in premature infants 11.7
6 peroxisome biogenesis disorder 2b 11.5
7 peroxisome biogenesis disorder 3b 11.5
8 peroxisome biogenesis disorder 4b 11.5
9 peroxisome biogenesis disorder 5b 11.5
10 peroxisome biogenesis disorder 6b 11.5
11 peroxisome biogenesis disorder 7b 11.5
12 peroxisome biogenesis disorder 11b 11.5
13 peroxisome biogenesis disorder 8b 11.4
14 zellweger spectrum disorder 11.4
15 peroxisome biogenesis disorder 1a 11.3
16 peroxisome biogenesis disorder 2a 11.2
17 peroxisome biogenesis disorder 3a 11.2
18 peroxisome biogenesis disorder 4a 11.2
19 peroxisome biogenesis disorder 5a 11.2
20 peroxisome biogenesis disorder 6a 11.2
21 peroxisome biogenesis disorder 7a 11.2
22 peroxisome biogenesis disorder 8a 11.2
23 peroxisome biogenesis disorder 9b 11.2
24 peroxisome biogenesis disorder 10a 11.2
25 peroxisome biogenesis disorder 11a 11.2
26 peroxisome biogenesis disorder 12a 11.2
27 peroxisome biogenesis disorder 13a 11.2
28 neonatal adrenoleukodystrophy 11.2
29 zellweger syndrome 11.1
30 bronchopulmonary dysplasia 10.6
31 patent ductus arteriosus 1 10.5
32 interstitial emphysema 10.5
33 middle east respiratory syndrome 10.3
34 heart disease 10.3
35 cholera 10.3
36 respiratory failure 10.3
37 pre-eclampsia 10.2
38 rapidly involuting congenital hemangioma 10.2
39 cardiogenic shock 10.2
40 colorectal cancer 10.1
41 myeloma, multiple 10.1
42 hydrocephalus 10.1
43 neonatal respiratory failure 10.1
44 bronchitis 10.1
45 gestational diabetes 10.1
46 disseminated intravascular coagulation 10.1
47 pulmonary edema 10.1
48 lung disease 10.1
49 exudative vitreoretinopathy 1 10.1
50 pneumonia 10.1

Graphical network of the top 20 diseases related to Respiratory Distress Syndrome, Infant:



Diseases related to Respiratory Distress Syndrome, Infant

Symptoms & Phenotypes for Respiratory Distress Syndrome, Infant

UMLS symptoms related to Respiratory Distress Syndrome, Infant:


dyspnea, hemoptysis, apnea, respiratory distress, cheyne-stokes respiration, coughing, hoarseness

Drugs & Therapeutics for Respiratory Distress Syndrome, Infant

Drugs for Respiratory Distress Syndrome, Infant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 291)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
2
Racepinephrine Approved Phase 4 329-65-7 838
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Zinc Approved, Investigational Phase 4 7440-66-6 32051
11
Coal tar Approved Phase 4 8007-45-2
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
15
Remifentanil Approved Phase 4 132875-61-7 60815
16
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
17 Poractant alfa Approved Phase 4 129069-19-8
18 Beractant Approved Phase 4 108778-82-1
19
Budesonide Approved Phase 4 51333-22-3 63006 5281004
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
21
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
22
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
23 Epinephryl borate Phase 4
24 Anesthetics, Inhalation Phase 4
25 BB 1101 Phase 4
26 Excitatory Amino Acid Antagonists Phase 4
27 Anesthetics, Dissociative Phase 4
28 Calciferol Phase 4
29 Angiotensin II Type 1 Receptor Blockers Phase 4
30 Angiotensinogen Phase 4
31 Angiotensin Receptor Antagonists Phase 4
32 Giapreza Phase 4
33 Antihypertensive Agents Phase 4
34 Calcium, Dietary Phase 4
35 Carotenoids Phase 4
36
Picolinic acid Phase 4 98-98-6 1018
37 Provitamins Phase 4
38 Chelating Agents Phase 4
39 Iron Chelating Agents Phase 4
40 Tin Fluorides Phase 4
41
Glycopyrrolate Phase 4 596-51-0 3494
42 Anti-Anxiety Agents Phase 4
43 GABA Modulators Phase 4
44 Psychotropic Drugs Phase 4
45 Mineralocorticoids Phase 4
46 Mineralocorticoid Receptor Antagonists Phase 4
47 diuretics Phase 4
48 Diuretics, Potassium Sparing Phase 4
49 Narcotics Phase 4
50 Analgesics, Opioid Phase 4

Interventional clinical trials:

(show top 50) (show all 827)
# Name Status NCT ID Phase Drugs
1 Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency Unknown status NCT00773058 Phase 4 hydrocortisone;placebo
2 Efficacy Evaluation of Surfactant Administration for Respiratory Distress Syndrome Treatment Via Laryngeal Mask Airway. A Randomized Controlled Trial Unknown status NCT01173237 Phase 4
3 Propofol and Remifentanil Versus Midazolam and Remifentanil as Premedication Allowing Very Early Extubation After Surfactant Treatment in Preterm Neonates With Respiratory Distress Syndrome Unknown status NCT00797160 Phase 4 propofol
4 Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI) Unknown status NCT00368680 Phase 4
5 Comparative Trial of Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams Unknown status NCT00277030 Phase 4 Surfactant
6 Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS Unknown status NCT01573715 Phase 4 NIMBEX;NIMBEX
7 Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT01763853 Phase 4 4% albumin
8 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
9 THE EFFECT OF SUSTAINED LUNG INFLATION MANEUVER APPLIED THROUGH NASAL PRONG ON EARLY AND LATE RESPIRATORY MORBIDITIES IN PRETERM INFANTS Unknown status NCT02887924 Phase 4
10 The Effect of Maternal Antenatal Steroid Administration on the Blood Flow Through the Pulmonary Artery in the Term Fetus; a Randomized Control Double Blinded Study Unknown status NCT02978976 Phase 4 Betamethasone;saline
11 An International, Open, Randomized, Controlled Study to Evaluate the Efficacy of Combining Prophylactic Curosurf® With Early Nasal CPAP Versus Early Nasal CPAP Alone in Very Preterm Infants at Risk of Respiratory Distress Syndrome Completed NCT00501982 Phase 4 Poractant alfa (Curosurf®)
12 Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant Completed NCT01941524 Phase 4 Poractant alfa instillation;Beractant instillation
13 Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants Completed NCT01741129 Phase 4
14 Comparative Study of the Use of Remifentanil Versus Morphine for Sedation and Analgesia of Premature Neonates During Mechanical Ventilation in the Treatment of Respiratory Distress Syndrome (RDS) Completed NCT00391105 Phase 4 Remifentanil
15 Effects of Bolus Surfactant Therapy on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants With Severe Respiratory Distress Syndrome Completed NCT01923844 Phase 4 exogenous surfactant
16 Premedication for Non-Emergency Endotracheal Intubation In the NICU Completed NCT01749501 Phase 4 Rocuronium
17 Effect of Early 48-hour Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients Presenting With Acute Respiratory Distress Syndrome (ARDS) : a Monocentric, Prospective, Randomized Study. Completed NCT02166853 Phase 4 sevoflurane;midazolam
18 Corticosteroid Mediates Acute Respiratory Distress Syndrome Via NLRP3 Inflammasome Signaling Pathway Completed NCT02819453 Phase 4 Methylprednisolone
19 Rescue Surfactant for Respiratory Distress Syndrome (RDS) in Newborns: Comparing Efficacy of Delivery Via Laryngeal Mask Airway to Delivery by Endotracheal Intubation Completed NCT01042600 Phase 4
20 Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress Completed NCT00486850 Phase 4
21 Effects Of A Recruitment Maneuver On Plasma Levels of sRAGE, The Soluble Form of The Receptor For Advanced Glycation End Products, In Patients With Diffuse Acute Respiratory Distress Syndrome (ARDS) Completed NCT01600651 Phase 4
22 The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients Completed NCT03337373 Phase 4 cisatracurium
23 A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome Completed NCT01731795 Phase 4 Dexamethasone
24 Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial Recruiting NCT04334629 Phase 4 Ibuprofen
25 Effect of Inhalation Sedation With Sevoflurane Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome (ARDS) Course. Recruiting NCT04014218 Phase 4 Inhalation Sedation;Intravenous Sedation
26 The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates Recruiting NCT03366584 Phase 4 Dexamethasone
27 Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection Recruiting NCT04359862 Phase 4 Sevoflurane;Propofol
28 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Recruiting NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
29 Efficacy of Rescue Surfactant Delivery Via Endotracheal Intubation (INSURE Technique) Versus Laryngeal Mask Airway (LMA) for Respiratory Distress Syndrome (RDS) in Preterm Neonates Recruiting NCT02164734 Phase 4 remifentanil
30 Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 Recruiting NCT04325061 Phase 4 Dexamethasone
31 PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease Recruiting NCT04335786 Phase 4 Valsartan (Diovan);Placebo oral tablet
32 Premedication for Less Invasive Surfactant Administration Recruiting NCT03735563 Phase 4 Ketamine;Fentanyl
33 Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
34 Sleep Intervention During Acute Lung Injury Active, not recruiting NCT01050699 Phase 4 Dexmedetomidine;Midazolam and Fentanyl
35 Comparison of Two Fraction Oxygen Inspired (FiO2) Thresholds for the Surfactant Administration in Preterm Infants With Respiratory Disease Syndrome: a Single-center Randomized Phase IV Clinical Trial Not yet recruiting NCT04199364 Phase 4 Poractant Alfa 80 mg/mL Intratracheal Suspension
36 The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients Not yet recruiting NCT04345887 Phase 4 Spironolactone 100mg;Placebo oral tablet
37 Effects of Positive End-expiratory Pressure With and Without Inspiratory Synchronization During Moderate to Severe ARDS Not yet recruiting NCT04241874 Phase 4
38 Stress Assessment in Preterm Infants With Respiratory Distress Syndrome Treated or Not With an Analgesic Drug During the Traditional or the Less Invasive Method of Surfactant Therapy. Not yet recruiting NCT04073173 Phase 4 Analgesic, Opioid
39 Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study Not yet recruiting NCT03275415 Phase 4 budesonide;Saline
40 Effects of Adding L‑Carnitine With Dexamethasone on Respiratory Distress Syndrome Development in Preterm Infants Suspended NCT03630367 Phase 4 Dexamethasone;L-Carnitine 1G/5mL Injection
41 Randomized Study Comparing the ASV to Conventional Ventilation for Intubated Patients During Inter-hospital Transfers. Controlled Randomized Monocentric Prospective Study Comparing ASV Versus Conventional Ventilation Modes Terminated NCT02348047 Phase 4
42 Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome. Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
43 Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants Terminated NCT00146497 Phase 4 Budesonide-Surfactant
44 Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial) Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
45 Pre Hospital Evaluation of Video Laryngoscopy : a Comparative Study of Macintosh and GLIDESCOPE Ranger® Withdrawn NCT01374061 Phase 4
46 Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome Unknown status NCT01265589 Phase 3 surfactant;surfactant+vitamin A
47 A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients Unknown status NCT00465374 Phase 3
48 Comparison Between Amniotic Fluid Lamellar Body Count and Fetal Pulmonary Artery Doppler Indices in Predicting Fetal Lung Maturity Unknown status NCT02331199 Phase 3
49 Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room. Unknown status NCT01517828 Phase 3 Sedation by ketamine;Sedation with Midazolam
50 Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial Unknown status NCT02774044 Phase 2, Phase 3 Cadisurf;Survanta

Search NIH Clinical Center for Respiratory Distress Syndrome, Infant

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Albumin Human, USP
ALBUMIN,AGGREGATED
ALBUMIN,EGG
ALBUMIN,HUMAN INJ
ALBUMIN,MICROSPHERE HUMAN SERUM
beractant
Colfosceril
colfosceril palmitate
Nitric Oxide
Poractant alfa

Genetic Tests for Respiratory Distress Syndrome, Infant

Anatomical Context for Respiratory Distress Syndrome, Infant

MalaCards organs/tissues related to Respiratory Distress Syndrome, Infant:

40
Lung, Bone, Testes, Fetal Lung, Heart, Neutrophil, Brain

Publications for Respiratory Distress Syndrome, Infant

Articles related to Respiratory Distress Syndrome, Infant:

(show top 50) (show all 81)
# Title Authors PMID Year
1
Anterior placenta previa in the mid-trimester of pregnancy as a risk factor for neonatal respiratory distress syndrome. 61
30388184 2018
2
Cytokine profiles at birth and the risk of developing severe respiratory distress and chronic lung disease. 61
28616049 2017
3
The Haplotype TGGAG in the ABCA3 Gene Increases the Risk of Respiratory Distress Syndrome in Preterm Infants in Southern China. 61
26522252 2016
4
[Clinical features, prevention and treatment of respiratory distress syndrome in neonates of different gestational ages in tertiary hospitals in Northwest China]. 61
26483220 2015
5
[Epidemiological survey of neonatal respiratory distress syndrome in part of northwest regions in China]. 61
26080663 2015
6
[A multicenter study on the surfactant treatment in late-preterm or term infants with respiratory distress syndrome]. 61
25537535 2014
7
Heliox non-invasive ventilation for preventing extubation failure in preterm infants. 61
23145834 2013
8
Relationship between respiratory impedance and positive end-expiratory pressure in mechanically ventilated neonates. 61
23306585 2013
9
Single ABCA3 mutations increase risk for neonatal respiratory distress syndrome. 61
23166334 2012
10
Impact of volume guarantee on synchronized ventilation in preterm infants: a randomized controlled trial. 61
22618094 2012
11
Expression of SP-C and Ki67 in lungs of preterm infants dying from respiratory distress syndrome. 61
23027351 2012
12
Frequency Modulation and Spatiotemporal Stability of the sCPG in Preterm Infants with RDS. 61
22888359 2012
13
Early postnatal surge of serum Clara cell secretory protein in newborn infants. 61
21952535 2012
14
Physical and physicochemical factors effecting transport of chlorohydrocarbon gases from lung alveolar air to blood as measured by the causation of narcosis. 61
22458856 2012
15
Metabolomic analysis of bronchoalveolar lavage fluid in preterm infants complicated by respiratory distress syndrome: preliminary results. 61
21781003 2011
16
Endothelin-1 and L-arginine in preterm infants with respiratory distress. 61
20700864 2011
17
Current status of neonatal acute respiratory disorders: a one-year prospective survey from a Chinese neonatal network. 61
21034580 2010
18
Surfactant administration for neonatal respiratory distress does not improve lung interstitial fluid clearance: echographic and experimental evidence. 61
20629494 2010
19
Pulmonary secretory phospholipase A2 in infants with respiratory distress syndrome stimulates in vitro neutrophil migration. 61
19478531 2010
20
[Retrospective analysis of elective caesarean section and respiratory distress syndrome in the term neonates]. 61
20021786 2009
21
Activation of T cells in preterm infants with respiratory distress syndrome. 61
19468239 2009
22
Respiratory Distress Syndrome Degrades the Fine Structure of the Non-Nutritive Suck In Preterm Infants. 61
19122873 2008
23
Free carnitine levels in respiratory distress syndrome during the first week of life. 61
17009198 2006
24
Evaluation of serum cortisol levels in a relatively large and mature group of ventilated and nonventilated preterm infants with respiratory distress syndrome. 61
16841278 2006
25
Cerebral oxygenation and cerebral oxygen extraction in the preterm infant: the impact of respiratory distress syndrome. 61
16506004 2006
26
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. 61
16188788 2005
27
Is carbon monoxide-mediated cyclic guanosine monophosphate production responsible for low blood pressure in neonatal respiratory distress syndrome? 61
15516362 2005
28
Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. 61
15650304 2005
29
Population based study on the outcome of small for gestational age newborns. 61
15613577 2005
30
[Mortality risk factors in premature infants with respiratory distress syndrome treated by mechanical ventilation]. 61
16053172 2005
31
Surfactant protein A and B genetic variants in respiratory distress syndrome in singletons and twins. 61
12947025 2003
32
Exhaled nitric oxide and tracheal endothelin-1 in preterm infants with and without RDS. 61
14520725 2003
33
Lung epithelial cells undergo apoptosis in neonatal respiratory distress syndrome. 61
12538783 2003
34
Prediction of respiratory distress syndrome using the Abbott FLM-II amniotic fluid assay. 61
12417097 2002
35
Cord serum lipid and apolipoprotein levels in preterm infants with the neonatal respiratory distress syndrome. 61
12375541 2002
36
Nitric oxide production and plasma cyclic guanosine monophosphate in premature infants with respiratory distress syndrome. 61
12373064 2002
37
Tracheobronchial aspirate fluid neutrophil lipocalin, elastase- and neutrophil protease-4-alpha1-antitrypsin complexes, protease inhibitors and free proteolytic activity in respiratory distress syndrome. 61
12412868 2002
38
Epidermal growth factor in the lungs of infants developing chronic lung disease. 61
11757630 2001
39
A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation. 61
11433048 2001
40
Study of plasma endothelin-1 concentrations in Taiwanese neonates with respiratory distress. 61
11413881 2001
41
Elevated type IV collagen in bronchoalveolar lavage fluid from infants with bronchopulmonary dysplasia. 61
11150828 2001
42
Surfactant proteins A and B as interactive genetic determinants of neonatal respiratory distress syndrome. 61
11063734 2000
43
Effect of patent ductus arteriosus and indomethacin treatment on serum cardiac troponin T levels in preterm infants with respiratory distress syndrome. 61
10789933 2000
44
Chronic lung disease in extremely low birth weight infants: a two-year retrospective analysis. 61
10927943 2000
45
Randomized controlled trial of volume-targeted synchronized ventilation and conventional intermittent mandatory ventilation following initial exogenous surfactant therapy. 61
10613781 2000
46
A prospective randomized comparison of conventional mechanical ventilation and very early high frequency oscillatory ventilation in extremely premature newborns with respiratory distress syndrome. 61
10051081 1999
47
Neonatal lung function in very immature infants with and without RDS. 61
10642959 1999
48
Measurement of protein flux with positron emission tomography in neonates. 61
10325807 1999
49
Indications of coagulation and/or fibrinolytic system activation in healthy and sick very-low-birth-weight neonates. 61
9742262 1998
50
A survey on the treatment strategy of patent ductus arteriosus in very low-birth-weight infants. 61
9553290 1998

Variations for Respiratory Distress Syndrome, Infant

Expression for Respiratory Distress Syndrome, Infant

Search GEO for disease gene expression data for Respiratory Distress Syndrome, Infant.

Pathways for Respiratory Distress Syndrome, Infant

GO Terms for Respiratory Distress Syndrome, Infant

Sources for Respiratory Distress Syndrome, Infant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....